Summary:
The TRIADTM study is evaluating the effectiveness, safety, and tolerability of an investigational medication that may reduce symptoms of agitation due to Alzheimer’s disease.
Agitation can be defined as the presence of one or more of the following behaviors:
- Excessive motor activity (eg, pacing or wandering)
- Verbal aggression (eg, screaming or cursing)
- Physical aggression (eg, hitting or kicking)
Agitation due to Alzheimer’s disease can make caring for your loved one challenging and stressful.
Your loved one may be eligible for the TRIADTM Research Study if he or she:
- Has moderate to severe agitation due to Alzheimer’s disease
- Is between 50 and 90 years of age
- Has a caregiver who is able to attend all study visits
Additionally, certain qualified patients may have the opportunity to receive the investigational medication for an additional year, as part of an extension study.
Qualified participants will receive study-related tests and procedures at no cost. In addition to evaluations, each study visit will also provide an opportunity for the participant and caregiver to meet with the study team, address any questions they may have, and share their experiences. Participants and/or caregivers may be compensated for their time and travel.